Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies: GlobalData Read more
Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData Read more